Albany, NY, Feb. 16, 2016 (GLOBE NEWSWIRE) -- A recent research report on breast cancer therapeutics in major developed markets has been added to the repository of ResearchMoz.us. The report, titled “Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence,” offers a detailed overview of the breast cancer therapeutics market across developed regions and studies the growth of the market across these regions. The report points out the key factors impacting the growth of the market and projects the growth of the overall market by 2021.
The report points out that the increased uptake of targeted and combination therapies for breast cancer has boosted the growth of the breast cancer therapeutics market across developed regions. The rapidly growing geriatric population and launch of premium-priced products with higher efficacy than the existing therapies have further augmented the market’s growth. However, high level of competition among the key players, patent expiries, and unfavorable reimbursement policies regarding premium-priced therapeutics will restrain the market in the coming years.
For more info, get a Sample PDF: http://www.researchmoz.us/enquiry.php?type=S&repid=536328
The report describes the treatment options for breast cancer such as surgery and radiation therapy, hormonal therapies, chemotherapy, and targeted therapies. Providing an overview of the marketed therapeutic products, the report compiles a list of breast cancer therapeutics drugs available in the market, such as Tykerb/Tier (lapatinib ditosylate monohydrate), Afinitor (everolimus), Perjeta (pertuzumab), Herceptin (trastuzumab), Ixempra (ixabepilone), Halaven (eribulin mesylate), Kadcyla (ado-trastuzumab emtansine), and Avastin (bevacizumab). The report makes a heat map of the marketed products and measures their effectiveness of treatment.
The report mentions the pipeline products in terms of molecular target, clinical trials, and duration. Under clinical trials, the report looks at the failure rate of the pipeline drugs for breast cancer, patient enrolment, and sample size of clinical trials. Some of the promising drugs in the pipeline are Buparlisib, Abemaciclib, Niraparib, Lynparza, Veliparib, Neratinib, and Ribociclib.
The report studies the growth of the breast cancer therapeutics market across North America, Europe, and Japan. The report studies the size of each of the regional markets with focus on treatment usage patterns and annual cost of therapy.
Browse Report description and TOC:
The report looks at the key deals and consolidations in the breast cancer therapeutics market across developed regions. Information about a number of prominent licensing deals has been included in the report, such as the licensing agreement between Sprint Bioscience and Bayer Healthcare, Takeda and ImmunoGen, Halozyme Therapeutics and Janssen Biotech, CTI BioPharma and Servier for Pixuvri, and Oncothyreon and Array BioPharma for ONT-380. Co-development deals such as the agreement between MacroGenics and Merck, the partnership between Color Genomics and the University of California Health, and the agreements between Liker and Celgene, and Santen Pharma and Tracon have been described in the report.
About Us
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.